Jim Simons Enlivex Therapeutics Ltd. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Renaissance Technologies LLC holds 74,789 shares of ENLV stock, worth $76,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,789

Previous 71,689 4.32%

Holding current value

$76,284

Previous $101,000 24.75%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.2 - $1.69 $3,720 - $5,239	3,100 Added 4.32%	74,789 $126,000
Q2 2024 Aug 09, 2024	BUY	$1.27 - $4.31 $2,286 - $7,757	1,800 Added 2.58%	71,689 $101,000
Q1 2024 May 13, 2024	BUY	$2.54 - $4.3 $19,812 - $33,540	7,800 Added 12.56%	69,889 $265,000
Q4 2023 Feb 13, 2024	BUY	$1.29 - $2.92 $4,128 - $9,344	3,200 Added 5.43%	62,089 $168,000
Q3 2023 Nov 14, 2023	BUY	$1.46 - $2.97 $3,212 - $6,534	2,200 Added 3.88%	58,889 $93,000
Q2 2023 Aug 11, 2023	BUY	$2.51 - $3.71 $5,020 - $7,420	2,000 Added 3.66%	56,689 $149,000
Q1 2023 May 12, 2023	BUY	$3.41 - $4.55 $1,705 - $2,275	500 Added 0.92%	54,689 $199,000
Q4 2022 Feb 13, 2023	SELL	$3.74 - $4.81 $17,578 - $22,606	-4,700 Reduced 7.98%	54,189 $213,000
Q3 2022 Nov 14, 2022	SELL	$4.11 - $5.87 $21,783 - $31,111	-5,300 Reduced 8.26%	58,889 $250,000
Q2 2022 Aug 12, 2022	BUY	$3.81 - $8.64 $1,905 - $4,320	500 Added 0.79%	64,189 $290,000
Q1 2022 May 13, 2022	SELL	$4.92 - $6.66 $19,680 - $26,640	-4,000 Reduced 5.91%	63,689 $356,000
Q4 2021 Feb 11, 2022	SELL	$5.81 - $9.73 $117,942 - $197,519	-20,300 Reduced 23.07%	67,689 $423,000
Q3 2021 Nov 12, 2021	SELL	$7.43 - $13.86 $800,337 - $1.49 Million	-107,717 Reduced 55.04%	87,989 $869,000
Q2 2021 Aug 13, 2021	SELL	$8.61 - $12.1 $815,367 - $1.15 Million	-94,700 Reduced 32.61%	195,706 $1.74 Million
Q1 2021 May 13, 2021	BUY	$9.26 - $24.0 $104,638 - $271,200	11,300 Added 4.05%	290,406 $3.22 Million
Q4 2020 Feb 10, 2021	SELL	$8.16 - $14.5 $158,304 - $281,300	-19,400 Reduced 6.5%	279,106 $2.35 Million
Q3 2020 Nov 13, 2020	BUY	$4.64 - $5.94 $124,351 - $159,192	26,800 Added 9.86%	298,506 $1.77 Million
Q2 2020 Aug 13, 2020	BUY	$4.4 - $6.4 $777,550 - $1.13 Million	176,716 Added 186.04%	271,706 $1.38 Million
Q1 2020 May 14, 2020	BUY	$3.77 - $9.91 $213,382 - $560,906	56,600 Added 147.43%	94,990 $445,000
Q4 2019 Feb 13, 2020	BUY	$6.61 - $27.48 $96,506 - $401,208	14,600 Added 61.37%	38,390 $322,000
Q3 2019 Nov 13, 2019	BUY	$19.7 - $39.42 $76,830 - $153,738	3,900 Added 19.61%	23,790 $635,000
Q2 2019 Aug 12, 2019	BUY	$8.32 - $21.5 $18,312 - $47,321	2,201 Added 12.44%	19,890 $428,000
Q1 2019 May 14, 2019	BUY	$6.8 - $15.4 $120,285 - $272,410	17,689 New	17,689 $219,000

Others Institutions Holding ENLV

# of Institutions

Shares Held

2.58M

Call Options Held

20.8K

Put Options Held

View Full List

About Enlivex Therapeutics Ltd.

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $18.8M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

More about ENLV

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account